SCHEMBL13685341

SCHEMBL13685341

Cc1ccc(Nc2cc(OC3CCN(C(=O)O)CC3)ncn2)c(Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.53
EGFR P00533 7/20 0.41
FLT3 P36888 3/20 0.41
CDK2 P24941 1/20 0.41
CDK6 Q00534 1/20 0.41
S1PR1 P21453 2/20 0.39
ERBB2 P04626 2/20 0.37
CYP2C9 P11712 1/20 0.37
RIPK2 O43353 1/20 0.36
RET P07949 1/20 0.36
MET P08581 1/20 0.36
EPHB2 P29323 1/20 0.36
TEC P42680 1/20 0.36
EPHB4 P54760 1/20 0.36
EPHA4 P54764 1/20 0.36
BTK Q06187 1/20 0.36
KCNH2 Q12809 1/20 0.36
TNK1 Q13470 1/20 0.36
RIPK3 Q9Y572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388449 0.88 GPR119 (0.70) GPR119CYP2C9KCNH2
SCHEMBL391509 0.88 GPR119 (0.54) GPR119
SCHEMBL4719749 0.83 GPR119 (0.45) GPR119EGFRFLT3CDK2CDK6
SCHEMBL4723041 0.83 GPR119 (0.55) GPR119FLT3CDK2CDK6S1PR1
SCHEMBL5264014 0.81 GPR119 (0.46) GPR119EGFRFLT3CDK2CDK6
SCHEMBL5264283 0.80 GPR119 (0.62) GPR119FLT3CDK2CDK6CYP2C9
SCHEMBL5188992 0.80 GPR119 (0.45) GPR119EGFRFLT3CDK2CDK6
SCHEMBL386785 0.79 GPR119 (0.80) GPR119CYP2C9KCNH2
SCHEMBL1073405 0.78 GPR119 (0.47) GPR119EGFRFLT3CDK2CDK6
SCHEMBL3866032 0.77 GPR119 (0.48) GPR119EGFRFLT3CDK2CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758565-B2 Method of identifying GLP-1 secretagogues ARENA PHARM INC (US) 2012-11-14 EP disclosed
CN-101420941-A Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies ARENA PHARM INC (US) 2009-04-29 CN disclosed